Limited effectiveness of radioiodine therapy for residual cervical lymph node metastases in radioiodine-naïve papillary thyroid cancer - Report - MDSpire
Advertisement
Limited effectiveness of radioiodine therapy for residual cervical lymph node metastases in radioiodine-naïve papillary thyroid cancer
Efficacy of Radioiodine Treatment for Persistent Cervical Lymph Node Metastases
Overview
This study evaluates the effectiveness of radioiodine (RAI) therapy in patients with papillary thyroid carcinoma (PTC) and persistent cervical lymph node metastases. The findings indicate that RAI-non-avid metastases are common, with modest response rates observed among RAI-avid lesions.
Background
Radioiodine therapy is a common treatment for cervical lymph node metastases in PTC, yet its efficacy for documented residual disease is uncertain. The American Thyroid Association guidelines recommend RAI for high-risk patients, but its role in intermediate-risk patients remains controversial, as noted in the 2025 guidelines.
Data Highlights
Response Type
RAI-Avid Nodes
All Nodes
Complete Response
38.5%
10.3%
Partial Response
20.5%
6.2%
No Objective Response
-
83.5%
Key Findings
39 out of 146 cervical lymph node metastases were RAI-avid (26.7%).
Complete and partial responses in RAI-avid nodes were 38.5% and 20.5%, respectively.
Among all nodes, complete and partial responses were 10.3% and 6.2%, with no objective response in 83.5% of cases.
At the patient level, a complete response was achieved in 11% (8/71) of patients.
RAI-non-avid disease was frequently observed in aggressive histologic subtypes.
Responders maintained an excellent response category at a median follow-up of 77 months.
Clinical Implications
The findings indicate that RAI-non-avid metastases are a significant factor in treatment outcomes, emphasizing the importance of understanding RAI-avidity of lesions.
Conclusion
The study highlights the limited efficacy of RAI therapy for persistent cervical lymph node metastases in PTC, particularly in cases of RAI-non-avid disease.
